14$ 4M C5.15 WL, DD + VOL!!! WOW staying ahead eda
Post# of 72
(Total Views: 502)
Posted On: 05/25/2018 4:45:08 PM
14$ 4M C5.15 WL, DD + VOL!!! WOW staying ahead eda(
on the hour chart!
NEW!!!
May 24, 2018 7:00 AM
ArQule Strengthens Executive Team with Two Key Appointments
BURLINGTON, Mass.
Newly Created Positions of Senior Vice President, Corporate Strategy, Communication & Finance and Senior Vice President, Program Management and Product Planning
ArQule, Inc. (NASDAQ: ARQL) today announced two strategic additions to its executive team, appointing Dr. Marc Schegerin as senior vice president, corporate strategy, communication and finance, and Dr. Shirish Hirani as senior vice president, program management and product planning.
“We are delighted to welcome both Marc and Shirish to ArQule’s executive team,” commented ArQule CEO, Paolo Pucci. “Marc’s medical background, paired with his experience in healthcare and investment banking, and Shirish’s expertise in both drug development and operations will be essential as ArQule continues to advance its precision medicine programs in both oncology and rare diseases.”
Dr. Schegerin joins ArQule with extensive experience in the pharmaceutical industry and healthcare investment banking. Prior to ArQule, Dr. Schegerin was a Healthcare Investment Banking Director at Citigroup. His prior experience includes Strategy and Development leadership roles at Sage Therapeutics and Biogen, and he began his career at Goldman Sachs. Dr. Schegerin received an M.D. from Dartmouth Medical School and an M.B.A. from the Tuck School of Business at Dartmouth.
Dr. Schegerin stated “It is an exceptional opportunity to join the team at ArQule. I look forward to working with the rest of the executive team to advance ArQule’s corporate strategy to deliver significant value for patients and shareholders.”
Until recently, Dr. Hirani was at ARIAD Pharmaceuticals as vice president, drug development. Prior roles at ARIAD include vice president of program and alliance management and vice president of development operations & planning. Dr. Hirani had executive program management and product development roles at other life science companies including Transkaryotic Therapies, Dyax, ImmuLogic and Genzyme. Dr. Hirani received a B.S. and Ph.D. from Queen Elizabeth College, University of London.
Dr. Hirani said “I am pleased to join ArQule at such an exciting time. I believe ArQule’s pipeline of clinical programs has great potential, and I look forward to further developing its biomarker defined oncology and rare disease programs.”
About ArQule
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s pipeline includes: ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options; Miransertib (ARQ 092), a selective inhibitor of the AKT serine/threonine kinase, in a phase 1/2 company sponsored study for Overgrowth Diseases, in a phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), and in Phase 1b in combination with the hormonal therapy, anastrozole, in patients with advanced endometrial cancer; ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; Derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds. You can follow us on Twitter and LinkedIn.
Related links
www.arqule.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180524005163/en/
Corporate Contact:
Marc Schegerin, MD, 781-994-0440
Senior Vice President, Head of Strategy & Finance
marc@arqule.com
or
Media Contact:
LifeSci Public Relations
Allison Blum, Ph.D., 646-627-8383
Allison@lifescipublicrelations.com
Copyright Business Wire 2018
News Provided by Business Wire via QuoteMedia
on the hour chart! NEW!!!
May 24, 2018 7:00 AM
ArQule Strengthens Executive Team with Two Key Appointments
BURLINGTON, Mass.
Newly Created Positions of Senior Vice President, Corporate Strategy, Communication & Finance and Senior Vice President, Program Management and Product Planning
ArQule, Inc. (NASDAQ: ARQL) today announced two strategic additions to its executive team, appointing Dr. Marc Schegerin as senior vice president, corporate strategy, communication and finance, and Dr. Shirish Hirani as senior vice president, program management and product planning.
“We are delighted to welcome both Marc and Shirish to ArQule’s executive team,” commented ArQule CEO, Paolo Pucci. “Marc’s medical background, paired with his experience in healthcare and investment banking, and Shirish’s expertise in both drug development and operations will be essential as ArQule continues to advance its precision medicine programs in both oncology and rare diseases.”
Dr. Schegerin joins ArQule with extensive experience in the pharmaceutical industry and healthcare investment banking. Prior to ArQule, Dr. Schegerin was a Healthcare Investment Banking Director at Citigroup. His prior experience includes Strategy and Development leadership roles at Sage Therapeutics and Biogen, and he began his career at Goldman Sachs. Dr. Schegerin received an M.D. from Dartmouth Medical School and an M.B.A. from the Tuck School of Business at Dartmouth.
Dr. Schegerin stated “It is an exceptional opportunity to join the team at ArQule. I look forward to working with the rest of the executive team to advance ArQule’s corporate strategy to deliver significant value for patients and shareholders.”
Until recently, Dr. Hirani was at ARIAD Pharmaceuticals as vice president, drug development. Prior roles at ARIAD include vice president of program and alliance management and vice president of development operations & planning. Dr. Hirani had executive program management and product development roles at other life science companies including Transkaryotic Therapies, Dyax, ImmuLogic and Genzyme. Dr. Hirani received a B.S. and Ph.D. from Queen Elizabeth College, University of London.
Dr. Hirani said “I am pleased to join ArQule at such an exciting time. I believe ArQule’s pipeline of clinical programs has great potential, and I look forward to further developing its biomarker defined oncology and rare disease programs.”
About ArQule
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s pipeline includes: ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options; Miransertib (ARQ 092), a selective inhibitor of the AKT serine/threonine kinase, in a phase 1/2 company sponsored study for Overgrowth Diseases, in a phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), and in Phase 1b in combination with the hormonal therapy, anastrozole, in patients with advanced endometrial cancer; ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; Derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds. You can follow us on Twitter and LinkedIn.
Related links
www.arqule.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180524005163/en/
Corporate Contact:
Marc Schegerin, MD, 781-994-0440
Senior Vice President, Head of Strategy & Finance
marc@arqule.com
or
Media Contact:
LifeSci Public Relations
Allison Blum, Ph.D., 646-627-8383
Allison@lifescipublicrelations.com
Copyright Business Wire 2018
News Provided by Business Wire via QuoteMedia
(0)
(0)ArQule Inc. (ARQL) Stock Research Links
The majority of my post are the top 20% gainer! To decode them its (ticker ID, % Changed, Volume, Close price and Float) I typically put V,C&F as a prefix to that number and use K, M and B as a suffix (Kilo, Million & Billion) for volume and float. I may also use S for Support and R for Resistance.
I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.
I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.